Moderna, Pharma Stocks Fall as FDA Names Industry Critic as Top Vaccine Regulator
Why Did Vertex Pharmaceuticals Stock Fall On Tuesday?
Express News | Shares of Vaccine and Gene Therapy Stocks Are Trading Lower After FDA Commissioner Marty Makary Reportedly Named Vinay Prasad as Director of the Center for Biologics and Research
Express News | 'FDA Names Vinay Prasad as New Head of Vaccines, Biologics'- Bloomberg Law
Neurocrine Biosciences' Ingrezza Q1 Sales Prove Resilient, Analysts Boost Price Target
Guggenheim Maintains Buy on Neurocrine Biosciences, Raises Price Target to $165
FARO Technologies, Celanese, Avient, Aramark And Other Big Stocks Moving Higher On Tuesday
Nike To $70? Here Are 10 Top Analyst Forecasts For Tuesday
Ichor Holdings Posts Weak Earnings, Joins Fabrinet, Vertex Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
This Vertex Pharmaceuticals Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Tuesday
Neurocrine Biosciences Analyst Ratings
Leerink Partners Downgrades Vertex Pharmaceuticals to Market Perform, Lowers Price Target to $503
Vertex Pharmaceuticals Analyst Ratings
Earnings Call Summary | Neurocrine Biosciences(NBIX.US) Q1 2025 Earnings Conference
Earnings Call Summary | Vertex Pharmaceuticals(VRTX.US) Q1 2025 Earnings Conference
Vertex Raises 2025 Revenue Guidance to $12B With Strong Launches and Pipeline Progress
Vertex Misses on Both Lines in Q1 as 2025 Revenue Forecast Narrowed
12 Health Care Stocks Moving In Monday's After-Market Session
Vertex Pharmaceuticals Stock Falls On Q1 Earnings, Revenue Miss — Company Raises Low End Of FY25 Revenue Guidance
Neurocrine Biosciences Non-GAAP EPS of $0.70 Misses by $0.39, Revenue of $572.6M Beats by $11.63M